GNBP released a 10K on Friday and I have found it to show that the company potentially has a lot in store for the upcoming 2012-2013 year! The company has aligned itself with the National Cancer Institute (NCI) where GNBP has entered into a Patent License Agreement with the National Institutes of Health, giving GNBP the non-exclusive worldwide right and license to develop and manufacture certain proprietary autologous tumor infiltrating lymphocyte adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal
Currently no other companies commercially provide a ready-to-infuse adoptive cell therapy product that competes with Contego within the proposed market of which GNBP operates. The company estimates approximately 6,000 –7,000 Stage IV metastatic melanoma patients could be candidates for Contego annually in the U.S.; nearly 10% of the annual number of new cases within the US!
The 10K also lays out an amazing team of scientists and clinicians from all over the US who have experience with the development and use of adoptive cell therapy using autologous tumor infiltrating lymphocytes for the treatment of cancer. They will assist with GNBP's development and commercialization of Contego. Represented institutes include the Fred Hutchinson Cancer Research Center, Yale University School of Medicine, the Lee Moffitt Cancer Center & Research Institute, the Anderson Cancer Center, City of Hope, as well as University of Pennsylvania School of Medicine!
With solid goals and a strong development team shown in the release of this 10K, I see a lot of potential with GNBP, where the stock could pop like I saw several days ago, seeing highs around $1.40.
